For Q1 FY2026 (ended March 31, 2026), Amgen reported revenue of $8.618 billion, up 5.8% year-over-year. Net income was $1.819 billion, up 5.1%, while operating income surged 126.3% to $2.666 billion. Diluted EPS rose 4.4% to $3.34. The company held $12.038 billion in cash, with equity of $9.190 billion and long-term debt of $57.323 billion.
•Revenue increased 5.8% YoY to $8.618 billion.
•Operating income more than doubled, rising 126.3% to $2.666 billion.
•Diluted EPS grew 4.4% to $3.34.
•Cash and equivalents stood at $12.038 billion, with long-term debt of $57.323 billion.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Amgen Inc. discovers develops, manufactures, and delivers human therapeutics globally. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.
Its portfolio also includes Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease, Prolia to treat postmenopausal women with osteoporosis, XGEVA for skeletal-related events prevention, Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization, Nplate for the treatment of patients with immune thrombocytopenia, KYPROLIS to treat patients with relapsed or refractory multiple myeloma, Aranesp to treat a lower-than-normal number of red blood cells and anemia, EVENITY for the treatment of osteoporosis in postmenopausal for women, Vectibix to treat patients with wild-type RAS metastatic colorectal cancer, BLINCYTO for the treatment of patients with acute lymphoblastic leukemia, TEPEZZA to treat thyroid eye disease, and KRYSTEXXA for the treatment of chronic refractory gout.
It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE.
Its portfolio also includes BEONE MEDICINES LTD. to develop and commercialize Aimovig, UCB for the development and commercialization of EVENITY, Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization, and BeiGene, Ltd. for oncology products expansion and development. Incorporated in 1980, the company is headquartered in Thousand Oaks, California.
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. Its principal products include Enbrel for rheumatoid arthritis and psoriasis, Otezla for plaque psoriasis and psoriatic arthritis, Prolia for osteoporosis in postmenopausal women, XGEVA to prevent skeletal-related events, Repatha to reduce cardiovascular risks, Nplate for immune thrombocytopenia, KYPROLIS for multiple myeloma, Aranesp for anemia, EVENITY for osteoporosis, Vectibix for colorectal cancer, BLINCYTO for acute lymphoblastic leukemia, TEPEZZA for thyroid eye disease, and KRYSTEXXA for chronic refractory gout. The company also markets other products such as TEZSPIRE, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, and PROCYSBI.
Where is Amgen (AMGN) listed and what currency does it trade in?
Amgen Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AMGN. Its shares are traded in United States Dollars (USD). As a US-based company, it is part of the US region and its stock is primarily traded on this major US exchange.
What sector and industry does Amgen (AMGN) belong to?
Amgen Inc. operates in the Healthcare sector and is classified under the Drug Manufacturers - General industry. This means it is a pharmaceutical company that develops and manufactures a wide range of therapeutic drugs. Its products address various medical conditions, including inflammatory diseases, oncology, bone health, cardiovascular disease, and rare diseases, making it a diversified player in the drug manufacturing space.
Where is Amgen (AMGN) headquartered and what markets does it serve?
Amgen Inc. is headquartered in the United States and serves a global market. The company distributes its products to healthcare providers such as physicians, clinics, dialysis centers, hospitals, and pharmacies worldwide. While its primary market is the US, its therapeutics are used internationally to treat patients with serious illnesses, including rheumatoid arthritis, osteoporosis, cancer, and cardiovascular disease.
How does Amgen (AMGN) make money?
Amgen generates revenue by selling its portfolio of human therapeutics globally. Its key products include Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, and KRYSTEXXA, among others. The company serves healthcare providers such as physicians, clinics, dialysis centers, hospitals, and pharmacies. By focusing on innovative treatments for chronic and life-threatening conditions, Amgen earns income from both established brands and newer therapies targeting oncology, inflammation, bone health, and rare diseases.